Bio-Rad Laboratories, Inc.
HealthcareNYSE:BIO · New York Stock Exchange
-$7.63 today
Vol 0.13M · Avg 0.38M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
10.2%
avg 5.1%
ROIC
2.0%
avg 2.1%
ROA
7.2%
avg 4.0%
Analysis
ROE is currently the strongest return metric at 10.2% versus its period average of 5.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Norman D. Schwartz | Chairman & Chief Executive Officer | $1.68M | — | 76 | $441,507.00 | 1.63% |
Jonathan DiVincenzo | President & Chief Operating Officer | $1.17M | — | 60 | $5,609.00 | 0.02% |
James J. Barry | Executive Vice President & President of Life Science Group | $1.11M | — | 48 | $509.68 | <0.01% |
Roop K. Lakkaraju | Executive Vice President & Chief Financial Officer | $984,424.00 | — | 55 | $2,983.90 | 0.01% |
Rajat Mehta | Executive Vice President of Global Commercial Operations | $649,798.00 | — | 47 | $0.00 | <0.01% |
Michael Crowley | Executive Vice President of Global Commercial Operations | $649,798.00 | — | 64 | $11,171.00 | 0.04% |
Erik Molitor | Senior Vice President of Global Technology & Systems | — | — | — | — | — |
Matthew Werner | Senior Vice President and Chief Compliance & Privacy Officer | — | — | — | — | — |
Ruben Argueta | Vice President of Investor Relations | — | — | — | — | — |
Yong Chung | Vice President of Investor Relations | — | — | — | — | — |
Courtney C. Enloe | Executive Vice President, General Counsel & Secretary | — | — | 54 | $372.00 | <0.01% |
Nanditha R. Yelamanchi | Executive Vice President of Global Human Resources | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
2
$349,885.51
Net Sentiment
$349,885.51
Net selling
Most Active
ENGELHARDT EVA ANETTE
1 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| May 11, 2026 | ENGELHARDT EVA ANETTE Direct | Sell | 550 | $246.54 | $135,597.00 | |
| Nov 6, 2025 | BARRY JAMES Direct | Sell | 699.873 | $306.18 | $214,288.51 |
Analysis
Insiders reported 0 buys worth $0.00 and 2 sells worth $349,885.51 over the last 12 months. That adds up to net selling of $349,885.51. ENGELHARDT EVA ANETTE was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -13.7% | +9.1% (15yr)1 analysts |
| Revenue | N/A | N/A | -0.8% | +2.4% (15yr)1 analysts |
| Net Income | N/A | N/A | -12.6% | +8.3% (15yr)1 analysts |
| EBIT | N/A | N/A | -14.2% | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -0.8% over three years. Forward estimates point to EPS at +9.1% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
DaVita Inc.
NYSE:DVA
$13.45B
Penumbra, Inc.
NYSE:PEN
$12.53B
Align Technology, Inc.
NASDAQ:ALGN
$12.51B
Globus Medical, Inc.
NYSE:GMED
$10.86B
Masimo Corporation
NASDAQ:MASI
$9.42B
Henry Schein, Inc.
NASDAQ:HSIC
$9.31B
Charles River Laboratories International, Inc.
NYSE:CRL
$9.06B
AptarGroup, Inc.
NYSE:ATR
$7.51B
HealthEquity, Inc.
NASDAQ:HQY
$7.38B
Grifols, S.A.
NASDAQ:GRFS
$6.50B
Who manages BIO?
Bio-Rad Laboratories, Inc. (BIO) lists 12 active executives. The top listed executive is Jonathan DiVincenzo, President & Chief Operating Officer.
Are BIO insiders buying or selling?
Recent insider activity shows net buying of $513,788.82.
Explore More
Continue the stock analysis
Jump to another research area for this company.